Respiratory syncytial virus

Respiratory syncytial virus
NIAID · CC BY 2.0 · source
Name	Respiratory syncytial virus
Virus group	negative-sense single-stranded RNA virus
Family	Pneumoviridae
Genus	Orthopneumovirus
Species	Human orthopneumovirus
Diseases	bronchiolitis, pneumonia

Respiratory syncytial virus is a leading cause of acute lower respiratory infection in infants and older adults, associated with seasonal epidemics and substantial global morbidity and mortality. Major public health bodies, pediatric hospitals, and vaccine developers prioritize surveillance, prevention, and therapeutic research due to RSV's impact on neonatal units, long-term care facilities, and community health systems.

Virology

Respiratory syncytial virus is an enveloped, negative-sense RNA virus in the family Pneumoviridae and genus Orthopneumovirus, characterized by surface glycoproteins including F and G that mediate cell entry and antigenicity; structural and functional studies are pursued by teams at National Institutes of Health, Institut Pasteur, and Centers for Disease Control and Prevention laboratories. The virus exhibits two major antigenic subgroups, A and B, identified through early work at institutions like Mayo Clinic, Johns Hopkins Hospital, and Royal Victoria Hospital, and ongoing genomic surveillance is conducted by consortia including GISAID, World Health Organization, and national reference centers. Molecular replication involves a nucleocapsid complex with the large polymerase (L) and phosphoprotein (P), concepts elucidated in research from Massachusetts Institute of Technology, University of Oxford, and University of Cambridge virology groups. Viral evolution and antigenic drift are tracked in collaboration with public health agencies such as Public Health England and research institutes including Karolinska Institutet and Cold Spring Harbor Laboratory.

Epidemiology

RSV epidemiology shows predictable seasonal peaks in temperate regions studied by Centers for Disease Control and Prevention and Public Health Agency of Canada; tropical patterns have been described by investigators at London School of Hygiene and Tropical Medicine and Harvard T.H. Chan School of Public Health. Global burden estimates published in reports from World Health Organization and analyses by Bill & Melinda Gates Foundation-funded teams indicate high hospitalization rates among infants in settings monitored by UNICEF, Pan American Health Organization, and national ministries of health. Transmission dynamics have been modeled by groups at Imperial College London, ETH Zurich, and University of Melbourne to inform interventions used by NHS England, Veterans Health Administration, and municipal health departments. Outbreak investigations in long-term care and neonatal intensive care units have been reported by Mayo Clinic, Mount Sinai Health System, and Johns Hopkins Hospital, prompting infection control policies in facilities overseen by Department of Health and Human Services and regional public health authorities.

Clinical features and pathogenesis

Clinical manifestations range from mild upper respiratory symptoms to severe bronchiolitis and pneumonia described in pediatric cohorts at Great Ormond Street Hospital, Boston Children's Hospital, and SickKids Hospital; risk factors include prematurity, congenital heart disease, and immunocompromise recognized by specialty societies such as American Academy of Pediatrics and European Society for Paediatric Infectious Diseases. Pathogenesis studies at Stanford University, Yale School of Medicine, and University of Toronto reveal that RSV induces airway epithelial damage, mucus plugging, and immune-mediated inflammation with contributions from neutrophils, T cells, and cytokines characterized in work at Roche, Novavax, and academic immunology centers. Severe disease epidemiology among older adults has been described in cohorts evaluated by Johns Hopkins Bloomberg School of Public Health, Mayo Clinic, and University College London Hospitals and is important for vaccine target selection by manufacturers including Pfizer and GSK. Long-term sequelae such as recurrent wheeze and asthma associations have been investigated by research teams at Karolinska Institutet, University of Copenhagen, and McMaster University.

Diagnosis and laboratory testing

Diagnostic approaches include antigen detection, nucleic acid amplification tests (NAATs), and viral culture performed in clinical laboratories accredited by bodies like College of American Pathologists and Clinical and Laboratory Standards Institute; test development has involved companies such as Abbott Laboratories, Roche Diagnostics, and Cepheid. NAAT sensitivity and point-of-care antigen tests are evaluated in multicenter trials coordinated by NIH, Wellcome Trust, and regional reference labs at ECDC and Public Health England. Serologic assays are used in epidemiologic studies by groups at University of Washington, Fred Hutchinson Cancer Center, and Imperial College London, while whole-genome sequencing for outbreak analysis is conducted by networks including GISAID, Wellcome Sanger Institute, and national public health laboratories.

Treatment and management

Supportive care—oxygen, hydration, and respiratory support—is the mainstay in hospitals such as Cleveland Clinic, Texas Children's Hospital, and Children's Hospital of Philadelphia following guidelines from American Academy of Pediatrics and National Institute for Health and Care Excellence. Antiviral therapy with ribavirin has limited use and is debated in specialty guidelines from Infectious Diseases Society of America and transplant centers like Mayo Clinic and Johns Hopkins Hospital. Monoclonal antibody prophylaxis (palivizumab) developed through collaborations including MedImmune and endorsed for high-risk infants by American Academy of Pediatrics remains an important preventive strategy, while newer therapeutics are in trials sponsored by Pfizer, AstraZeneca, and Moderna.

Prevention and control

Prevention strategies include maternal immunization, long-acting monoclonal antibodies, and pediatric vaccines under development by manufacturers such as GSK, Pfizer, Sanofi, and Moderna, with regulatory review by agencies including U.S. Food and Drug Administration, European Medicines Agency, and Health Canada. Infection control recommendations for healthcare settings are issued by World Health Organization, Centers for Disease Control and Prevention, and national public health agencies; strategies have been implemented in hospitals like Johns Hopkins Hospital and Massachusetts General Hospital during seasonal peaks. Public health vaccination campaigns and immunization policy decisions are informed by advisory committees such as Advisory Committee on Immunization Practices and national immunization technical advisory groups.

History and research directions

RSV was first isolated in the 1950s by teams at Mayo Clinic and Johns Hopkins Hospital and later named and characterized through work at National Institutes of Health and Institut Pasteur; landmark clinical descriptions appeared in journals affiliated with American Medical Association and British Medical Journal. Current research directions include structure-based vaccine design pioneered at Vaccine Research Center (NIH), monoclonal antibody engineering at Regeneron and AstraZeneca, and immunopathogenesis studies at Rockefeller University and Harvard Medical School. Ongoing global surveillance and implementation research are coordinated by World Health Organization, GAVI, and philanthropic funders such as Bill & Melinda Gates Foundation to guide equitable access strategies in collaboration with national ministries and partner organizations including UNICEF.

Category:Viruses